HC Deb 02 February 1999 vol 324 cc588-9W
Dr. Harris

To ask the Secretary of State for Scotland if he will list the research and development expenditure by(a) his Department and (b) the NHS, indicating separately that on health technology assessment in each year since 1992. [68208]

Mr. Galbraith

The Chief Scientist Office (CSO) within The Scottish Office Department of Health (SODoH) has responsibility for managing funds which support research activity to further the development of patient care and health services within the NHS in Scotland. CSO expenditure on research and development (R&D) for each year since 1992–93 is given in column(a) of the following table. CSO R&D expenditure on health technology assessment cannot be identified separately for each year since 1992–93 except at disproportionate cost. For 1998–99, it is expected to be about £1.9 million.

Up to and including 1995–96, Additional Cost of Teaching (ACT) was an element of the SODoH revenue allocations to Health Boards to protect the NHS support for both clinical teaching and clinical research costs. It is not possible to identify NHS R&D expenditure separately until 1996–97, when those within the NHS who were delivering R&D support services were invited to bid for costs incurred from the R&D Support Fund. NHS expenditure on R&D since 1996–97 is shown in column (b) of the following table.

Under the R&D Support Fund bidding procedure, bidders are asked to identify research activity areas, but these may be broad and encompass a range of subjects. It is not possible therefore to identify separately NHS R&D expenditure on health technology assessment except at disproportionate cost. From 1 July 1999 this will be a matter for the Scottish Parliament.

Research and development expenditure in Scotland
£ million
(a) SODoH: CSO (b) NHS
1992–93 8.9 Not available1
1993–94 10.6
1994–95 10.1
1995–96 10.7
1996–97 10.6 24.0
1997–98 9.9 28.0
1998–99 11.02 28.52
1 Additional Cost of Teaching (ACT) up to and including 1995–96 encompassed both clinical teaching and clinical research costs (no breakdown available)
2 Estimate

Forward to